JP5555494B2 - 癌を治療するためのアミノ化ヒドロキシキノリン類誘導体 - Google Patents
癌を治療するためのアミノ化ヒドロキシキノリン類誘導体 Download PDFInfo
- Publication number
- JP5555494B2 JP5555494B2 JP2009554065A JP2009554065A JP5555494B2 JP 5555494 B2 JP5555494 B2 JP 5555494B2 JP 2009554065 A JP2009554065 A JP 2009554065A JP 2009554065 A JP2009554065 A JP 2009554065A JP 5555494 B2 JP5555494 B2 JP 5555494B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- methylene
- hydroxyquinoline
- cancer
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 19
- 201000011510 cancer Diseases 0.000 title claims description 12
- 238000011282 treatment Methods 0.000 title description 5
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 111
- -1 tert-butyl 8-hydroxyquinolin-5-yl (4-methylbenzyl) Chemical group 0.000 claims description 62
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 12
- 208000005017 glioblastoma Diseases 0.000 claims description 12
- 238000013508 migration Methods 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000005012 migration Effects 0.000 claims description 7
- MNYNYYDIQMZGNK-UHFFFAOYSA-N 5-(naphthalen-1-ylmethylamino)quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1NCC1=CC=CC2=CC=CC=C12 MNYNYYDIQMZGNK-UHFFFAOYSA-N 0.000 claims description 5
- IKFSFDAHWNPUFJ-UHFFFAOYSA-N 5-[(8-hydroxyquinolin-5-yl)-(naphthalen-1-ylmethyl)amino]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1N(C=1C2=CC=CN=C2C(O)=CC=1)CC1=CC=CC2=CC=CC=C12 IKFSFDAHWNPUFJ-UHFFFAOYSA-N 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000017830 lymphoblastoma Diseases 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- LQRGIKZXNZEGIX-UHFFFAOYSA-N 5-[[(8-hydroxyquinolin-5-yl)-[(4-methylphenyl)methyl]amino]methyl]quinolin-8-ol Chemical compound C1=CC(C)=CC=C1CN(C=1C2=CC=CN=C2C(O)=CC=1)CC1=CC=C(O)C2=NC=CC=C12 LQRGIKZXNZEGIX-UHFFFAOYSA-N 0.000 claims description 4
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010027406 Mesothelioma Diseases 0.000 claims description 3
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 3
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 3
- 201000002313 intestinal cancer Diseases 0.000 claims description 3
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 208000013371 ovarian adenocarcinoma Diseases 0.000 claims description 3
- 201000006588 ovary adenocarcinoma Diseases 0.000 claims description 3
- LWPMUMIMHKHREW-UHFFFAOYSA-N 5-[[benzyl-[(8-hydroxyquinolin-5-yl)methyl]amino]methyl]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CN(CC=1C2=CC=CN=C2C(O)=CC=1)CC1=CC=CC=C1 LWPMUMIMHKHREW-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- UZLVOUQDHARTLZ-UHFFFAOYSA-N 5-methylidene-6h-quinolin-8-ol Chemical group C1=CN=C2C(O)=CCC(=C)C2=C1 UZLVOUQDHARTLZ-UHFFFAOYSA-N 0.000 description 47
- 210000004027 cell Anatomy 0.000 description 47
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 44
- 125000004433 nitrogen atom Chemical group N* 0.000 description 32
- MDAXKAUIABOHTD-UHFFFAOYSA-N 1,4,8,11-tetraazacyclotetradecane Chemical compound C1CNCCNCCCNCCNC1 MDAXKAUIABOHTD-UHFFFAOYSA-N 0.000 description 29
- 125000005843 halogen group Chemical group 0.000 description 21
- 229910052731 fluorine Inorganic materials 0.000 description 20
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 19
- 125000003118 aryl group Chemical group 0.000 description 19
- 229910052794 bromium Inorganic materials 0.000 description 19
- KUFDRRWNPNXBRF-UHFFFAOYSA-N 1,4,8,12-tetrazacyclopentadecane Chemical class C1CNCCCNCCNCCCNC1 KUFDRRWNPNXBRF-UHFFFAOYSA-N 0.000 description 17
- 125000005842 heteroatom Chemical group 0.000 description 17
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 125000001624 naphthyl group Chemical group 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 229910052717 sulfur Inorganic materials 0.000 description 14
- 125000000217 alkyl group Chemical group 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 229910052740 iodine Inorganic materials 0.000 description 12
- 150000002678 macrocyclic compounds Chemical class 0.000 description 12
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 11
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 11
- 229910052801 chlorine Inorganic materials 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000005090 green fluorescent protein Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 125000005037 alkyl phenyl group Chemical group 0.000 description 9
- 230000001093 anti-cancer Effects 0.000 description 9
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 125000004432 carbon atom Chemical group C* 0.000 description 8
- TYKPOYYBBXXZCE-UHFFFAOYSA-N 2-methylidene-1h-quinolin-8-ol Chemical group C1=CC(=C)NC2=C1C=CC=C2O TYKPOYYBBXXZCE-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- LOQUUTPFPMJDLD-UHFFFAOYSA-N 5-[[(8-hydroxyquinolin-5-yl)-[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CN(C=1C2=CC=CN=C2C(O)=CC=1)CC1=CC=C(C(F)(F)F)C=C1 LOQUUTPFPMJDLD-UHFFFAOYSA-N 0.000 description 5
- 102000011727 Caspases Human genes 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 4
- JGOBHUWKRDXZEY-UHFFFAOYSA-N 5-(chloromethyl)quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=C(CCl)C2=C1 JGOBHUWKRDXZEY-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- AAKOKTIJLYZXOB-UHFFFAOYSA-N 5-[[8-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradec-1-yl]methyl]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CN(CCNCCC1)CCCNCCN1CC(C=C1)=CC=C1CN1CCCNCCNCCCNCC1 AAKOKTIJLYZXOB-UHFFFAOYSA-N 0.000 description 3
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004163 cytometry Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229960003540 oxyquinoline Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960004964 temozolomide Drugs 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- NALBASRKDSIWNQ-UHFFFAOYSA-N 1,11-bis[(2-methylpropan-2-yl)oxy]-1,4,8,11-tetrazacyclotetradecane Chemical compound CC(C)(C)ON1CCCN(OC(C)(C)C)CCNCCCNCC1 NALBASRKDSIWNQ-UHFFFAOYSA-N 0.000 description 2
- DYZDEGISFJEHAA-UHFFFAOYSA-N 1,4,8,11-tetrazacyclopentadecane Chemical group C1CCNCCNCCCNCCNC1 DYZDEGISFJEHAA-UHFFFAOYSA-N 0.000 description 2
- DOMZDICZCBHSNT-UHFFFAOYSA-N 5-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CN1CCCNCCNCCCNCC1 DOMZDICZCBHSNT-UHFFFAOYSA-N 0.000 description 2
- QQAISVITWCCCIC-UHFFFAOYSA-N 5-(1,4,8,12-tetrazacyclopentadec-8-ylmethyl)quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CN1CCCNCCCNCCNCCC1 QQAISVITWCCCIC-UHFFFAOYSA-N 0.000 description 2
- CKFSZNNHRZDPJV-UHFFFAOYSA-N 5-[(benzylazaniumyl)methyl]quinolin-8-olate Chemical compound C12=CC=CN=C2C(O)=CC=C1CNCC1=CC=CC=C1 CKFSZNNHRZDPJV-UHFFFAOYSA-N 0.000 description 2
- NBMGFSVUCFXOOP-UHFFFAOYSA-N 5-[[(4-methylphenyl)methylamino]methyl]quinolin-8-ol Chemical compound C1=CC(C)=CC=C1CNCC1=CC=C(O)C2=NC=CC=C12 NBMGFSVUCFXOOP-UHFFFAOYSA-N 0.000 description 2
- YOPMGSIGGFDHPL-UHFFFAOYSA-N 5-[[11-[(8-hydroxyquinolin-5-yl)methyl]-1,4,8,11-tetrazacyclotetradec-1-yl]methyl]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CN(CCNCCCNCC1)CCCN1CC1=CC=C(O)C2=NC=CC=C12 YOPMGSIGGFDHPL-UHFFFAOYSA-N 0.000 description 2
- HUMSZQCAIUEDCY-UHFFFAOYSA-N 5-[[3-[(8-hydroxyquinolin-5-yl)methylamino]propylamino]methyl]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CNCCCNCC1=CC=C(O)C2=NC=CC=C12 HUMSZQCAIUEDCY-UHFFFAOYSA-N 0.000 description 2
- KENDWMBZHXRDQC-UHFFFAOYSA-N 5-[[[4-[[(8-hydroxyquinolin-5-yl)methylamino]methyl]phenyl]methylamino]methyl]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CNCC(C=C1)=CC=C1CNCC1=CC=C(O)C2=NC=CC=C12 KENDWMBZHXRDQC-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 0 C*c1c(*)c(*)c(C(C)*)c(*=*)c1O Chemical compound C*c1c(*)c(*)c(C(C)*)c(*=*)c1O 0.000 description 2
- 102000047934 Caspase-3/7 Human genes 0.000 description 2
- 108700037887 Caspase-3/7 Proteins 0.000 description 2
- 102000004091 Caspase-8 Human genes 0.000 description 2
- 108090000538 Caspase-8 Proteins 0.000 description 2
- 102000004039 Caspase-9 Human genes 0.000 description 2
- 108090000566 Caspase-9 Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000002095 anti-migrative effect Effects 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- JDHXHOMUEYWRGQ-UHFFFAOYSA-N ditert-butyl 4,8-bis[(8-hydroxyquinolin-5-yl)methyl]-1,4,8,11-tetrazacyclotetradecane-1,11-dicarboxylate Chemical compound C1CCN(CC=2C3=CC=CN=C3C(O)=CC=2)CCN(C(=O)OC(C)(C)C)CCCN(C(=O)OC(C)(C)C)CCN1CC1=CC=C(O)C2=NC=CC=C12 JDHXHOMUEYWRGQ-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007758 minimum essential medium Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MKXQRBASHXALMA-UHFFFAOYSA-N tritert-butyl 12-[(8-hydroxyquinolin-5-yl)methyl]-1,4,8,12-tetrazacyclopentadecane-1,4,8-tricarboxylate Chemical compound C1CCN(C(=O)OC(C)(C)C)CCN(C(=O)OC(C)(C)C)CCCN(C(=O)OC(C)(C)C)CCCN1CC1=CC=C(O)C2=NC=CC=C12 MKXQRBASHXALMA-UHFFFAOYSA-N 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- AOUOVFRSCMDPFA-QSDJMHMYSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-methylbutanoyl]amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O AOUOVFRSCMDPFA-QSDJMHMYSA-N 0.000 description 1
- UEUPDYPUTTUXLJ-UHFFFAOYSA-N 1-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane;octahydrochloride Chemical class Cl.Cl.Cl.Cl.Cl.Cl.Cl.Cl.C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 UEUPDYPUTTUXLJ-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- HULKIXRFKRCRHD-UHFFFAOYSA-N 4-[(2-acetamido-4-methylpentanoyl)amino]-5-[[1-[[3-carboxy-1-oxo-1-[[2-oxo-4-(trifluoromethyl)chromen-7-yl]amino]propan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound C=1C=C2C(C(F)(F)F)=CC(=O)OC2=CC=1NC(=O)C(CC(O)=O)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(NC(C)=O)CC(C)C)CC1=CN=CN1 HULKIXRFKRCRHD-UHFFFAOYSA-N 0.000 description 1
- DOVAIILGKBUWDI-UHFFFAOYSA-N 5-[[4-[(8-hydroxyquinolin-5-yl)methyl]piperazin-1-yl]methyl]quinolin-8-ol Chemical compound C12=CC=CN=C2C(O)=CC=C1CN1CCN(CC=2C3=CC=CN=C3C(O)=CC=2)CC1 DOVAIILGKBUWDI-UHFFFAOYSA-N 0.000 description 1
- XFZZDIHCNHYESF-UHFFFAOYSA-N 7-amino-1-bromo-4-phenyl-5,7,8,9-tetrahydrobenzo[7]annulen-6-one Chemical compound C=12CC(=O)C(N)CCC2=C(Br)C=CC=1C1=CC=CC=C1 XFZZDIHCNHYESF-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 238000010293 colony formation assay Methods 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 125000000853 cresyl group Chemical group C1(=CC=C(C=C1)C)* 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical group CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 230000000235 effect on cancer Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- IBBLKSWSCDAPIF-UHFFFAOYSA-N thiopyran Chemical compound S1C=CC=C=C1 IBBLKSWSCDAPIF-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- DCRHTUSFGYTZTJ-UHFFFAOYSA-N tritert-butyl 11-[(8-hydroxyquinolin-5-yl)methyl]-1,4,8,11-tetrazacyclotetradecane-1,4,8-tricarboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN(C(=O)OC(C)(C)C)CCN(C(=O)OC(C)(C)C)CCCN1CC1=CC=C(O)C2=NC=CC=C12 DCRHTUSFGYTZTJ-UHFFFAOYSA-N 0.000 description 1
- MEIGWXOSGUSCMV-UHFFFAOYSA-N tritert-butyl 11-[(8-hydroxyquinolin-5-yl)methyl]-1,4,8,12-tetrazacyclopentadecane-1,4,8-tricarboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCCN(C(=O)OC(C)(C)C)CCN(C(=O)OC(C)(C)C)CCCNC1CC1=CC=C(O)C2=NC=CC=C12 MEIGWXOSGUSCMV-UHFFFAOYSA-N 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR07/02154 | 2007-03-23 | ||
| FR0702154A FR2913976B1 (fr) | 2007-03-23 | 2007-03-23 | Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers. |
| PCT/FR2008/000399 WO2008135671A2 (fr) | 2007-03-23 | 2008-03-25 | Dérivés de la classe des hydroxyquinoléines aminées pour le traitement de cancers. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010522147A JP2010522147A (ja) | 2010-07-01 |
| JP2010522147A5 JP2010522147A5 (https=) | 2013-12-12 |
| JP5555494B2 true JP5555494B2 (ja) | 2014-07-23 |
Family
ID=38686734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554065A Expired - Fee Related JP5555494B2 (ja) | 2007-03-23 | 2008-03-25 | 癌を治療するためのアミノ化ヒドロキシキノリン類誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8324243B2 (https=) |
| EP (1) | EP2139860A2 (https=) |
| JP (1) | JP5555494B2 (https=) |
| CN (1) | CN101641332B (https=) |
| AU (1) | AU2008248475B2 (https=) |
| CA (1) | CA2680803A1 (https=) |
| FR (1) | FR2913976B1 (https=) |
| WO (1) | WO2008135671A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2913976B1 (fr) * | 2007-03-23 | 2013-04-26 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers. |
| EP2149567A1 (en) * | 2008-07-18 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Cyclic polyamines for binding phosphatidylserine |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| KR101514285B1 (ko) | 2013-08-09 | 2015-04-22 | 숙명여자대학교산학협력단 | 아미노다이하이드로퀴놀린 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 암 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5736192A (en) * | 1980-08-13 | 1982-02-26 | Nippon Oil Co Ltd | Metal inactivator and its composition |
| IL130324A0 (en) * | 1999-06-07 | 2000-06-01 | Yeda Res & Dev | Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators |
| US8058442B2 (en) * | 2002-11-07 | 2011-11-15 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| CN1295218C (zh) * | 2004-06-18 | 2007-01-17 | 中国科学院广州化学研究所 | 单官能团8－羟基喹啉金属配合物的烯类单体及其制法和用途 |
| FR2913976B1 (fr) * | 2007-03-23 | 2013-04-26 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers. |
-
2007
- 2007-03-23 FR FR0702154A patent/FR2913976B1/fr not_active Expired - Fee Related
-
2008
- 2008-03-25 US US12/532,695 patent/US8324243B2/en not_active Expired - Fee Related
- 2008-03-25 CA CA002680803A patent/CA2680803A1/en not_active Abandoned
- 2008-03-25 JP JP2009554065A patent/JP5555494B2/ja not_active Expired - Fee Related
- 2008-03-25 AU AU2008248475A patent/AU2008248475B2/en not_active Ceased
- 2008-03-25 CN CN200880007473.7A patent/CN101641332B/zh not_active Expired - Fee Related
- 2008-03-25 EP EP08787845A patent/EP2139860A2/fr not_active Withdrawn
- 2008-03-25 WO PCT/FR2008/000399 patent/WO2008135671A2/fr not_active Ceased
-
2012
- 2012-11-30 US US13/690,137 patent/US8614230B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8614230B2 (en) | 2013-12-24 |
| AU2008248475A1 (en) | 2008-11-13 |
| CN101641332A (zh) | 2010-02-03 |
| US20130102630A1 (en) | 2013-04-25 |
| EP2139860A2 (fr) | 2010-01-06 |
| CA2680803A1 (en) | 2008-11-13 |
| AU2008248475B2 (en) | 2013-10-03 |
| WO2008135671A3 (fr) | 2009-05-22 |
| CN101641332B (zh) | 2014-03-12 |
| FR2913976B1 (fr) | 2013-04-26 |
| JP2010522147A (ja) | 2010-07-01 |
| FR2913976A1 (fr) | 2008-09-26 |
| US8324243B2 (en) | 2012-12-04 |
| WO2008135671A2 (fr) | 2008-11-13 |
| US20100120856A1 (en) | 2010-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3749253B2 (ja) | 環状ポリアミン | |
| JP3176935B2 (ja) | ドーパミンリセプタサプタイプ特異性リガンドとしてのｎ―アミノアルキルジベンゾフランカルボキサミド | |
| JP2010519337A (ja) | カルバメート化合物 | |
| TWI750782B (zh) | 吲哚啉酮化合物及其用途 | |
| JP5555494B2 (ja) | 癌を治療するためのアミノ化ヒドロキシキノリン類誘導体 | |
| JP4897938B2 (ja) | Ｎ−［６−（ｃｉｓ−２，６−ジメチルモルホリン−４−イル）ピリジン−３−イル］−２−メチル−４’−（トリフルオロメトキシ）［１，１’−ビフェニル］−３−カルボキサミドの塩 | |
| JP6987125B2 (ja) | 新規２，４，６−三置換ｓ−トリアジン化合物並びにその製造方法および使用 | |
| EP3440070B1 (en) | Mdr-reversing 8-hydroxy-quinoline derivatives | |
| JP6768716B2 (ja) | カルボプラチンベースの共結晶の医薬組成物及びその用途 | |
| JP7301856B2 (ja) | インドールアミン－２，３－ジオキシゲナーゼ阻害剤およびその調製方法と使用 | |
| JP2008515979A (ja) | フラザノ‘３，４−ビピラジン（ｂｉｐｙｒａｚｉｎｅ）及び抗腫瘍剤としてのその使用 | |
| BRPI0619551A2 (pt) | derivados de jasmonato aprimorados, composições farmacêuticas e métodos de uso dos mesmos | |
| JP6695875B2 (ja) | 抗がん剤としての新規な１，３，５−トリアジン系ｐｉ３ｋ阻害剤及びその製造方法 | |
| AU2017219131A1 (en) | N- (3- { [ (3- { [2-chloro-5- (methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phe nyl) - 2 -methylalaninamide as phosphatidylinositol 3 - kinase inhibitor for the treatment of lymphoproliferative malignancies | |
| WO2021062168A1 (en) | Synthetic sphingolipid inspired molecules with heteroaromatic appendages, methods of their synthesis and methods of treatment | |
| TW201231470A (en) | 4-anilinofuro[2,3-b]quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | |
| WO2025012634A1 (en) | Carbazole compounds and their use in therapy, in the treatment of a respiratory infection | |
| WO2025008012A1 (en) | Pyrroloquinolines and their use as tubuline assembly inhibitors | |
| CA3039191A1 (en) | Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia | |
| WO2023238919A1 (ja) | ハイブリッド型化合物又はその塩 | |
| AU2015316886B2 (en) | 4-oxo-N-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer | |
| CN114478691A (zh) | 一种嵌合分子及其制备方法和应用 | |
| JPS6251653A (ja) | 新規２−ニトロソベンゾフエノン誘導体 | |
| OA16810A (en) | N- (3- {[(3- {[2-chloro-5-(methoxy) phenyl] amino} quinoxalin- 2 -yl) amino] sulfonyl} phenyl) 2 -methylalaninamide as phosphatidylinositol 3 kinase inhibitor for the treatment of lymphoproliferative malignancies. | |
| HK1239656B (en) | 4-oxo-n-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110323 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120309 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130418 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130423 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130723 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130730 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130822 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130829 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130920 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130930 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20131023 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20131119 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140318 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20140425 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140513 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140602 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5555494 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |